---
title: "Salubris released its performance for the first half of the year, with a net profit attributable to the parent company of 365 million yuan, an increase of 6.10%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253614677.md"
description: "Salubris released its 2025 semi-annual report, with operating revenue of 2.131 billion yuan, a year-on-year increase of 4.32%; net profit attributable to the parent company of 365 million yuan, a year-on-year increase of 6.10%. The net profit excluding non-recurring gains and losses was 347 million yuan, a year-on-year increase of 3.93%. The basic earnings per share were 0.33 yuan. The company has built a differentiated product portfolio in the hypertension field, with significant improvements in performance from patent and new product sales"
datetime: "2025-08-19T10:43:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253614677.md)
  - [en](https://longbridge.com/en/news/253614677.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253614677.md)
generator: "portal-rs"
---

# Salubris released its performance for the first half of the year, with a net profit attributable to the parent company of 365 million yuan, an increase of 6.10%

According to the Zhitong Finance APP, Salubris (002294.SZ) released its semi-annual report for 2025, showing an operating income of 2.131 billion yuan, a year-on-year increase of 4.32%. The net profit attributable to shareholders of the listed company was 365 million yuan, a year-on-year increase of 6.10%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 347 million yuan, a year-on-year increase of 3.93%. The basic earnings per share were 0.33 yuan.

During the reporting period, the sales of patents and new products saw significant growth, greatly enhancing revenue contribution, which has become a core pillar of the company's performance growth. In the field of hypertension, the company has built a differentiated product portfolio that continues to expand, accurately covering the medication needs of different patients, from Xinlitai (ARB class), Xinchao Tuo (ARNI class), to Fuli Tain® (ARB/CCB class compound preparation), and Fuli An® (ARB/diuretic class compound sustained-release preparation)

### Related Stocks

- [002294.CN](https://longbridge.com/en/quote/002294.CN.md)

## Related News & Research

- [Vishnusurya Projects and Infra's (NSE:VISHNUINFR) Weak Earnings May Only Reveal A Part Of The Whole Picture](https://longbridge.com/en/news/305559929.md)
- [Pondy Oxides And Chemicals Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected](https://longbridge.com/en/news/305560101.md)
- [Alkem Laboratories Limited (NSE:ALKEM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates](https://longbridge.com/en/news/305559747.md)
- [RioCan Real Estate Investment Trust (TSX:REI.UN) Expands Its Buyback Program, Is It Still Undervalued?](https://longbridge.com/en/news/305557624.md)
- [Kava Lend loses roughly $3.8 million to hack, sending KAVA token down nearly 40%](https://longbridge.com/en/news/305556359.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**